Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Apr 14;20(6):350. doi: 10.1038/s41577-020-0313-6

Human antibodies can neutralize SARS-CoV-2

Jovani Catalan-Dibene 1,
PMCID: PMC7186926  PMID: 32286538

In this preprint, Ju et al. demonstrate the existence of virus-specific memory B cells recognizing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein in patients infected with SARS-CoV-2. They observed crossreactivity of antibodies from patients infected with SARS-CoV-2 against spike proteins, but not against the RBD, of SARS-CoV-1 and MERS-CoV. Through single-cell sorting and BCR sequencing, they generated 206 SARS-CoV-2 RBD-specific monoclonal antibodies. Antibodies were from diverse families of immunoglobulin genes, without any apparent enrichment for specific families. Only two clones showed 98–99% blocking of viral entry, which correlated with high competing capacity against ACE2 receptor. These results indicate that the humoral response is virus specific and diverse and can produce potent neutralizing antibodies.

Competing interests

The author declares no competing interests.

References

Original article

  1. Ju B, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv. 2020 doi: 10.1101/2020.03.21.990770. [DOI] [PubMed] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES